Marker Therapeutics shares are trading higher after the company reported pre-clinical data of its MT-601 multiTAA-specific T cell product candidate MT-601 in lymphoma cells.
Portfolio Pulse from Benzinga Newsdesk
Marker Therapeutics reported positive pre-clinical data for its MT-601 multiTAA-specific T cell product candidate in lymphoma cells, causing its shares to trade higher.
May 31, 2023 | 12:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Marker Therapeutics shares are trading higher after positive pre-clinical data for its MT-601 product candidate in lymphoma cells.
The positive pre-clinical data for Marker Therapeutics' MT-601 product candidate in lymphoma cells indicates potential success in future clinical trials. This news is likely to increase investor confidence in the company, leading to a short-term increase in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100